Opus Genetics Q2 FY26 net loss widens to $8.1 million; revenue drops to $755,000

Reuters2026/08/06 11:11

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Opus Genetics posted a net loss of USD 8.1 million, or USD 0.08 per basic share, for the quarter ended June 30, 2026.
Revenue fell 73.8% to USD 755,000, on lower license and collaborations revenue tied primarily to its Viatris reimbursement arrangement.
R&D expense rose 86.1% to USD 11.21 million, due to higher manufacturing and clinical costs, partly offset by lower phentolamine program costs.
Cash and cash equivalents climbed to USD 88.81 million at June 30, with runway into 2029 expected including potential Oberland facility funding.
OPGx-BEST1 Cohort 1 topline data is expected in the second week of September; OPGx-LCA5 Phase 3 enrollment completed, dosing planned for Q4.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Opus Genetics Q2 FY26 net loss widens to $8.1 million; revenue drops to $755,000

You may also like

Crypto prices